US20050152980A1 - Pharmeutical microparticles - Google Patents

Pharmeutical microparticles Download PDF

Info

Publication number
US20050152980A1
US20050152980A1 US10/506,822 US50682204A US2005152980A1 US 20050152980 A1 US20050152980 A1 US 20050152980A1 US 50682204 A US50682204 A US 50682204A US 2005152980 A1 US2005152980 A1 US 2005152980A1
Authority
US
United States
Prior art keywords
microparticles
water
active ingredient
polymer
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/506,822
Inventor
Michael Ausborn
Olovier Lambert
Oskar Nagele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20050152980A1 publication Critical patent/US20050152980A1/en
Priority to US12/218,639 priority Critical patent/US8110224B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AUSBORN, MICHAEL, NAGELE, OSKAR, LAMBERT, OLIVIER
Priority to US13/348,114 priority patent/US8460709B2/en
Priority to US13/871,064 priority patent/US20130236550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Definitions

  • the invention relates to microparticles comprising at least one biologically degradable polymer, optionally at least one water soluble polymer and at least one pharmacologically active ingredient distributed in the polymer containing a phospholipid or lecithin and a process for their preparation.
  • Microparticles comprising a mixture of a biologically degradable polymer and a water-soluble polymer, into which a pharmaceutical active ingredient, preferably peptides, polypeptides or proteins, are incorporated, are known from U.S. Pat. No. 5,869,103. It is mentioned that an undesired initial high release of active ingredient, especially surface-active proteins, may be suppressed it, during production of the particles, a stabiliser, for example surfactants such as sorbitan monostearate or glyceryl monostearate, is added to the organic phase of an active ingredient emulsion or suspension. When active ingredient is released in contact with a physiological medium, such surfactants are washed out particularly quickly, so that the microparticle composition changes. Therefore, these surface active agents will stay in the polymer matrix for a very short period and will not prevent a possible adsorption of the drug substance to the polymer matrix during the release period. Therefore, a release of active ingredient over a longer period is not achieved.
  • J. L. Cleland describes the encapsulation of a recombinant human growth hormone with a biologically degradable polymer, for example a copolycondensate comprising lactic acid and glycolic acid.
  • a biologically degradable polymer for example a copolycondensate comprising lactic acid and glycolic acid.
  • the initial high release of active ingredient can only be reduced, and the possible denaturing of the hormone is avoided by adding trehalose or mannitol.
  • H. K. Tim et al describe that the encapsulation of the recombinant human growth hormone in a copolycondensate comprising lactic acid and glycolic acid leads to systems which have a high initial release of hormone of up to over 50% and afterwards no longer release any active ingredient.
  • M. Morlock et al. European Journal of Pharmaceutics and Biopharmaceutics 43 (1997), pages 29-361 and B. Bittner et al.
  • the invention provides microparticles comprising
  • the microparticles may have an irregular and preferably essentially spherical shape.
  • the particle diameter of the individual microparticles may be 0.1 to 200 ⁇ m, preferably 1 to 100 ⁇ m, most preferably 1 to 50 ⁇ m. Microparticles having an average particle diameter in the range of 5 to 80 ⁇ m, preferably 30 to 70 ⁇ m, are preferred.
  • the particle size may be controlled, for example, by adjusting the process parameters and by selecting solvents, polymers and the molecular weight of the polymers employed.
  • the microparticles may be compact and essentially pore-free particles, or porous particles with a compact or porous surface.
  • biologically degradable polymers means for example those polymers that are decomposed in a physiological medium. Hydrolytically degradable polymers are basically appropriate for this.
  • Bioly degradable polymers are known and are, in part, commercially obtainable. They may be, for example homo- or copolyesters of dicarboxylic acids, alkylene diols, polyalkylene glycols and/or aliphatic hydroxycarboxylic acids; homo- or copolyamides of dicarboxylic acids, alkylene diamines, and/or aliphatic aminocarboxylic acids; corresponding polyester-polyamide copolymers, polyanhydrides, polyorthoesters, polyphosphazenes and polycarbonates.
  • Suitable dicarboxylic acids are, for example, terephthalic acid and especially saturated aliphatic acids of formula HOOC—(C n H 2n )—COOH, wherein n is 0 or a number from 1 to 6 (oxalic, malonic, succinic or adipic acid).
  • Alkylene diols may correspond for example to HO—(C x H 2x )—OH, wherein x is a number from 1 to 6 (ethane-, propane-, butane-, pentane- or hexanediol).
  • the hydroxycarboxylic acids may correspond to formula HO—(C x H 2x )—COOH, wherein x is a number from 1 to 6 (hydroxyacetic acid, hydroxypropionic acid, hydroxybutanoic acid, hydroxypentanoic acid, hydroxyhexanoic acid).
  • the aminocarboxylic acids may correspond to formula H 2 N—(C x H 2x )—COOH, wherein x is a number from 1 to 6 (aminoacetic acid, aminopropionic acid, aminobutanoic acid, aminopentanoic acid, aminohexanoic acid).
  • the polyalkylene glycols in question may be, for example, oligomers of ethylene glycol or propylene glycol with ca.
  • Polycarbonates may contain recurring structural elements of formula —CO—(C x H 2x )—O, wherein x is a number from 1 to 6.
  • the molecular weight of the polymers may be, for example, 500 to 1,000,000, preferably 1000 to 500,000, most preferably 2000 to 100,000 daltons.
  • the biologically degradable polymers may be linear, branched and optionally crosslinked.
  • star polymers may also be used, in which polymer chains are bonded to the functional groups (for example hydroxyl, amino and/or carboxyl groups) of a core monomer, such as saccharides.
  • functional groups for example hydroxyl, amino and/or carboxyl groups
  • core monomer such as saccharides.
  • Such polymers are known and are partly commercial.
  • Preferred biologically degradable polymers are selected from the group of polycarbonates, and in particular the polyesters and polyamides of aliphatic hydroxycarboxylic acids or aminocarboxylic acids. Homo- and copolycondensates of ⁇ -hydroxycarboxylic acids are especially preferred, for example glycolic acid and lactic acid.
  • the ratio of monomers in copolycondensates may be, for example, 10:1 to 1:10, preferably 1:4 to 4:1.
  • Especially preferred polycondesates are poly-L- or poly-D,L-lactic acid.
  • Preferred copolycondensates are poly-D,L-lactide/glycolides with a monomer ratio of ca. 1:1 and a molecular weight of 5000 to 100,000 daltons. Mixtures of biologically degradable polymers may also be used.
  • the biologically degradable polymers are essentially insoluble in water.
  • Water-soluble polymers are likewise known and available commercially. They may be, for example, homo- or copolyoxa-alkylene oxides of preferably ethylene and/or propylene glycol, polyacrylamides and hydroxyalkylated polyacrylamides, polymaleic acid and the partial esters or amides thereof, polyacrylic acid and the partial esters or amides thereof, polyvinyl alcohol and the partial esters or ethers thereof, polyvinyl imidazole, polyvinyl pyrrolidone, and natural polymers, for example starch or chitosan. Polyvinyl pyrrolidone is preferred.
  • the water-soluble polymers may have molecular weights of 1000 to 500,000, preferably 1000 to 100,000, most preferably 1000 to 20,000 daltons. Mixtures of water-soluble polymers may also be used. The water-soluble polymers should also be soluble in organic solvents.
  • the amount of biologically degradable polymers may be, for example, 99 to 1% by weight, preferably 90 to 50% by weight, and the amount of water-soluble polymers may be 1 to 99% by weight, preferably 10 to 50% by weight, based on the composition of the polymers.
  • the microparticles contain at least one water-insoluble surfactant from the group of lecithins and phospholipids, the addition of which ensures that the active ingredient is protected against adsorption on the polymer matrix during the whole release period. Due to this effect the invention provides microparticles with extended release of an active ingredient.
  • Lecithins and phospholipids are known and are available commercially. These surfactants may be extracted from natural products such as eggs or soya.
  • the lecithins in question are natural, partly hydrogenated and hydrogenated lecithins or sphingolipids. Natural lecithins are mixtures of different phospholipids.
  • phospholipids examples include phosphatidyl choline, phosphatidyl ethanolamine, lysophosphatidyl choline, phosphatidyl glycerine, phosphatidic acid and phosphatidyl serine, as well as the partially or fully hydrogenated derivatives thereof.
  • Examples of phospholipids with defined fatty acids are 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerine, 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-glycerine and 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerine.
  • Lecithin and phosphatidyl choline are preferably used.
  • the amount of lecithins and/or phospholipids may be 0.01 to 90% by weight, preferably 0.1 to 70% by weight, most preferably 0.1 to 20% by weight, based on the total composition of the microparticles.
  • the lecithins and phospholipids are essentially uniformly distributed throughout the volume of the microparticles. Insofar as the lecithins or phospholipids are only partly soluble or insoluble in the solvent of the polymer solution, the formation of a dispersion of these substances in the polymer solution may be sufficient to achieve the effects according to the invention.
  • the pharmacologically active ingredients are in general those that are stable under the preparation conditions. Water-soluble active ingredients are preferred. Peptides, polypeptides and proteins are preferred according to the invention, especially those which adhere to the surface of microparticles because of their surface-active properties and lead to the formation of agglomerates. Further examples are carbohydrates, oligonucleotides, RNA and DNA. A few examples of peptides, polypeptides and proteins are antibodies, growth hormones, insulin, interferons, erythropoietin, calcitonin, heparin, somatostatins, cell-stimulating factors and parathyroid hormones. The aqueous solutions may contain buffers and electrolytes, for example NaCl. Examples of interferons are interferons of the alpha group, preferably interferon alpha 2a or alpha 2b, most preferably interferon alpha 2b.
  • the amount of active ingredient in the microparticles may be 0.1 to 90% by weight, preferably 1 to 70% by weight, most preferably 1 to 20% by weight, based on the weight of the microparticles.
  • the water-insoluble and surface-active substances are hereby added to the polymer solution, thereby providing optimum protection of the pharmacologically active ingredients during encapsulation and good distribution of the substance in the polymer of the microparticles.
  • the particles may be produced, for example by dispersing solid active ingredients or emulsifying liquid active ingredients or active ingredient solutions in physiologically compatible solvents in a polymer solution containing at least one surface-active substance, and subsequently removing the solvent. Evaporation may be undertaken at high agitation speeds in order to form the particles. It is expedient to carry out spray-drying.
  • Microparticles may also be produced by precipitating the polymer through the addition of a solvent, in which a polymer is insoluble, at high agitation speeds, whereby the pharmacologically active ingredient or the solution of an active ingredient is embedded in the polymer of the formed microparticles.
  • the invention provides a method of producing microparticles by forming polymers from polymer precursors (for example monomers and/or prepolymers) in a dispersion or emulsion of an active ingredient or active ingredient solution with the polymer precursors at high agitation speeds. Dispersed or emulsified pharmacologically active ingredient is hereby coated and precipitated by separating the polymer.
  • polymer precursors for example monomers and/or prepolymers
  • microparticles may be formed by using encapsulation by means of polymer separation in multi-phase systems of aqueous and organic media, which are similarly known.
  • aqueous solutions, dispersions or emulsions of active ingredient in an organic polymer solution it is possible to emulsify this emulsion in turn in water, in order to then form the microparticles by removing the solvent.
  • solutions, dispersions or emulsions of active ingredient in an organic solvent can also be emulsified in water, this emulsion is then emulsified in an organic polymer solution, and afterwards the polymer is then precipitated by adding a solvent which is immiscible with the polymer solution.
  • the water-insoluble and surface-active substances are hereby added to the polymer solution, thereby providing optimum protection for the active ingredients during encapsulation, with good distribution of the substance in the polymer of the microparticles.
  • Water-soluble pharmacologically active ingredients and in particular water-soluble, optionally surface-active peptides, polypeptides and proteins are preferably used as the aqueous formulation for encapsulation, whereby it is particularly advantageous to form the microparticles in a three-phase system.
  • a further object of the invention is a process for the preparation of microparticles, comprising the steps
  • the aqueous solution of process step a) may contain 0.01 to 80%, preferably 0.1 to 60%, most preferably 0.1 to 30% by weight of pharmacologically active ingredient, based on the aqueous solution.
  • the solution may contain stabilising agents and/or water-soluble thickeners. If peptides, polypeptides or proteins are used, it is expedient to add pH buffers, e.g. phosphate buffers. In the case of peptides, polypeptides or proteins, it is also advantageous to add protecting agents, for example glycine or sugar.
  • the components may be mixed and dissolved by stirring, optionally whilst heating. Any insoluble constituents can be filtered off before further use.
  • the polymers and the surface-active substance are conveniently dissolved whilst stirring, optionally with heating. Any insoluble constituents can be filtered off before further use.
  • the amount of biologically degradable polymer in the solution may be, for example, 1 to 60%, preferably 0 to 50% by weight, the amount of water-soluble polymer 0 to 50% by weight, and the amount of surface-active substance 1 to 80%, preferably 2 to 40% by weight, whereby the percentages by weight add up to 100%.
  • Suitable solvents, which are immiscible with water are for example hydrocarbons, halogenated hydrocarbons and ketones.
  • Preferred solvents are halogenated hydrocarbons, for example chloroform, ethane trichloride or tetrachloride, and in particular methylene dichloride.
  • the solutions are mixed by agitating at high speed.
  • the volume ratio of solution a) to solution b) may be, for example, from 1:1 to 1:50, preferably from 1:2 to 1:10.
  • this emulsion forming step may be carried out in a particularly advantageous manner by using a gear pump.
  • Rotary gear pump may be based on meshing gears.
  • Gear pumps are positive displacement pumps utilizing a set of gears as the displacement device.
  • the fluid pumps may have e.g. helical gears (angled teeth), spur gears (straight teeth), or herringbone gears.
  • a typical gear pump includes at least two and sometimes at least three gears including a drive gear and a driven gear housed within a pumping chamber.
  • Gear pumps are preferred by the present applicants because of their quiet operation, hydraulic efficiency, conjugate mechanical motion, constant sealing of the surfaces between the mating gear flanks and the minimum entrapment of fluid between the teeth that are in contact.
  • the gear pump may have a high load carrying capacity and run more smoothly.
  • the gear pump may be based on cavity technology.
  • Such gear pumps typically consist of a housing having an inlet, a liquid conduit and an outlet.
  • a gear cavity In the housing is a gear cavity, within which gears meshingly engage and rotate. Liquid enters the gear cavity near the engagement of the gears and on a side wherein the gear teeth are disengaging. As liquid enters the gear cavity it is entrained between the gear teeth and the walls of the gear cavity and moved along the periphery of the gear cavity until it reaches the point at which the gear teeth engage. This action sets up a pressure differential between the liquid inlet and the liquid outlet causing liquid flow.
  • Gear pumps are preferred pumps to create the shear stress in a closed chamber without creation of air/liquid interfaces that are detrimental to the stability of sensitive active ingredient as proteins and peptides.
  • a pump having a magnetic drive is used for aseptic manufacture of microparticles.
  • the pump head is coupled with the driving pump and can be easily removed for sterilization.
  • a magnetic drive pump may have an outer annular magnet turned or rotated by a motor.
  • An annular inner magnet may be disposed within the outer magnet and may be carried on a pump shaft.
  • the inner magnet may be isolated from the outer magnet by a thin metallic or plastic cup.
  • the inner magnet of such pumps may include a magnet and flux ring assembly which operates in the liquid that is moved through a system by the pump.
  • the gear pump may have suction shoes of the type shown in U.S. Pat. No. 4,127,365 the edge of the shoe fitting within the groove in each gear and bearing against the bottom of the groove.
  • the shoe may form a passageway from the liquid inlet duct in the gear block (which is covered by the shoe) to the mesh point of the gear teeth.
  • the shoe may fit over the mesh point of the gears and at least a span of two teeth to either side thereof, also fitting over the inlet duct and thus isolating this area from the main pump cavity to establish a small pump chamber within the pump cavity. Since there is a pressure differential when the pump is operating which is lower on the underside of the shoe than in the main pump cavity, the shoe is held against the pump block. The shoe separates the inlet duct from the discharge pressure, while accepting fluid flow.
  • Such pumps may be the Micropump Ismatex brand obtained e.g. from Ismatec A G, Germany or Allschwil, Basel Switzerland.
  • a typical model is IP65
  • Typical flow rates may be e.g from about 1 ml/min to about 12000 ml/min e.g 300 ml/min
  • Typical drive speeds may be e.g from about 60 rpm to about 6000 rpm e.g 3000 rpm
  • Typical differential pressures may be e.g from about 0.1 to about 5.2 bar (75 psi).
  • the present invention provides the unforeseen use of gear pumps to form emulsions.
  • gear pumps emulsions may be formed in an aseptic environment.
  • Emulsion (d) is subsequently mixed with water (c) whilst stirring at high speed to form a water in oil in water emulsion.
  • the water may contain stabilisers, for example polyvinyl alcohol or gelatin and buffers.
  • the amount of stabilisers may be 0.01 to 20%, preferably 0.01 to 10% by weight, based on the aqueous solution of the stabiliser.
  • this emulsion step is carried out using a static mixer.
  • a static mixer e.g a static laminar mixing device homogenization may be effected by the flow through the mixer.
  • these devices have been built up of the so-called static mixer elements. These elememts may be present to upset the flow of the liquids and mix them. Shear forces may be determinated by the number and type of mixing elements and by the flow of liquids through the static mixer.
  • Such laminar mixers may be employed in mixing devices for the mixing of low-viscosity soluble additives to high-viscosity liquids.
  • the lower-viscosity (limpid) liquid may be fed to the main flow of the highre-viscosity (viscid) liquid, e.g., via a tube which may be arranged before or directly at the inlet to the mixer.
  • Energy required for liquid flow may be produced by pumps or the like.
  • a typical mixer is Sulzer Mixer SMXS DN6 obtainable from Sulzer A G, Winterthur, Switzerland.
  • Typical flow rates of the first liquid (e.g. the internal phase) containing the organic solvent may be e.g from about 1 ml/min to about 12000 ml/min e.g 20 ml/min.
  • Typical flow rates of the second liquid (e.g. the continuous phase) containing water may be e.g from about 1 m/min to about 12000 ml/min e.g 400 ml/min
  • Typical pressure drops may be e.g from about 0.1 to about 5.2 bar (75 psi)
  • Process steps b) to f) are preferably carried out at room temperature.
  • Removal of the organic solvent is advantageously undertaken with further stirring and by applying a vacuum.
  • Heating can mean a temperature of up to ca. 60° C.
  • microparticles may optionally be washed to purify them (to remove organic solvent and surfactants such as polyvinyl alcohol or gelatin) and then isolated by sedimentation or optionally by filtration and dried to remove water and any residual solvents.
  • organic solvent and surfactants such as polyvinyl alcohol or gelatin
  • the known freeze-drying process is an especially suitable process for this.
  • Process step f) may be replaced by cross-flow filtration.
  • Cross-flow filtration affords the circulation of the microparticle suspension tangentially to a membrane e.g. a polymer membrane (Polyethersulfone Pall membrane type Omega), e.g. a ceramic membrane, e.g. hollow fibers or e.g. spiral wound systems.
  • the pore size of these membranes may be from 0.1 to 1 micrometer, preferably 0.8 micrometer for microfiltration.
  • For ultrafiltration membranes with molecular weight cut off ranging from 100 to 1,000,000 daltons are used.
  • the suspension is recirculated untill organic solvents and surfactants as e.g. polyvinyl alcohol or e.g. gelatin are removed. Microparticles may collected by sedimentation or by filtration.
  • microparticles therefrom having a controlled, predictable, and narrow cell size distribution may be obtained.
  • Typical flow rates tangentially over the membrane are e.g. from about 1 ml/min to about 100,000 ml/min e.g. 15,000 ml/min
  • Typical pressure drops may be e.g. from about 0.01 to about 5 bars.
  • microparticles are obtained in the form of free-flowing powders, which can be easily handled and further processed.
  • the microparticles are essentially free from agglomerates.
  • Microparticles may be resuspended in an aqueous solution containing a bulking agent (e.g. mannitol or sucrose). This suspension may be freeze-dried to get lyophilized microparticles with advantageous storage properties.
  • a bulking agent e.g. mannitol or sucrose
  • the structure of the microparticles depends mainly on the preparation process, the consistency of the active ingredients or their solutions, and the choice of polymers or polymer mixtures.
  • Encapsulation of solid active ingredients and of active ingredients dispersed in polymer solutions leads to essentially compact particles with little to no porosity. Release of the active ingredient in contact with a physiological medium is determined in the case of such particles by the decomposition of the polymer. Release can be accelerated by adding water-soluble polymers, since porous structures can be formed through the dissolving of water-soluble polymers. The surface-active substance then protects the active ingredient, so that a delayed release of active ingredient remains assured.
  • an aqueous solution containing the active ingredient is emulsified in the polymer solution.
  • the water contained in droplets of this primary emulsion are removed and the previous droplets form then cavities in the -dried polymer matrix.
  • the cavities are distributed randomly throughout the volume.
  • the size of the cavities distributed throughout the volume depends on the particle size, the process parameters, the selected polymers, their quantitative composition, and the type and amount of surface-active substance.
  • the diameter of the cavities may be, for example, from 0.01 to 100 ⁇ m, depending on the size of the microparticles.
  • the cavities are partially or wholly filled with an aqueous, solution of at least one pharmacologically active ingredient.
  • the microparticles may have pores in the surface area, especially if water-soluble polymers are used concurrently during preparation, or if solutions, emulsions and dispersions of active ingredient are not fully encapsulated in the surface area.
  • the microparticles according to the invention are notable for the delayed release behaviour of the pharmaceutical active ingredient in a physiological medium.
  • An initially excessive release also called initial burst
  • a subsequent complete breakdown of the release of active ingredient is not observed, even if surface-active peptides, polypeptides or proteins are used.
  • the delayed release of active ingredient in, for example, blood plasma can be maintained until the pharmacologically active ingredient in the particles has been used up, which can last for several days up to 12 months, depending on the amount and especially on the polymer used.
  • the release of active ingredient may be essentially constant, whereby in the first stage a higher amount, for example 10 to 70% of the total amount of active ingredient, is delivered in a shorter space of time.
  • an optimum dosage can be set, which will suffice for long-term action with single or multiple administration.
  • the release of an active ingredient may last from several days up to 8 weeks.
  • the starpolymer poly-D,L-lactide/glycolide together with interferon alpha 2b the invention provides a favourable release profile over at least 21 days. 10% to 60% of the active ingredient are released in the 2 to 5 days and the remaining active ingredient over a period of at least 21 days.
  • microparticles do not contain lecithin or phospholipid in the biologically degradable polymer, then in contrast to the particles according to the invention, no active ingredient is delivered after the initial burst phase.
  • a water-soluble polymer is additionally incorporated in the polymer matrix consisting of biologically degradable polymer and lecithin or phospholipid, then the active substance is released faster due to the creation of additionnal pores in the polymer matrix. The release period is then shortened and the release process is then essentially based on diffusion and not on a combination of diffusion and polymer degradation.
  • microparticles according to the invention are suitable for formulating in solid, pasty and liquid formulations for oral application (tablet, coated tablet, capsule, drinking solution or suspension), for parenteral application (syringes for intravenous or intramuscular administration, infusion with suspensions), suppositories for rectal or vaginal application, aerosols for application by inhalation, powders, creams, gels and transdermal systems for subcutaneous application, and drops for nasal or ophthalmic application.
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • a phosphate buffer pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid.
  • Solutions a) and b) are emulsified for 10 minutes using a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 270 ml per minute.
  • a gear pump Ismatec® MCP-Z, pump head P1830
  • the primary emulsion is pumped by a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 20 ml per minute
  • the aqueous phase is pumped by a gear pump (Ismatec® MCP-Z, pump head P130) at 575 rpm and at a pump capacity of 400 ml per minute in a mixing vessel (Statischemischer® SMXS DN6)
  • microparticles are filtered off, dried in a vacuum, and the pre-dried microparticles undergo freeze-drying.
  • a free-flowing powder consisting of microparticles with an average diameter of 60-70 ⁇ m is obtained.
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 2 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • a phosphate buffer pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid.
  • Steps d to g are carried out as described in example A1.
  • a free-flowing powder consisting of microparticles with an average diameter of 60-70 ⁇ m is obtained.
  • Steps d to g are carried out as described in example A1.
  • a free-flowing powder consisting of microparticles with an average diameter of 60-70 ⁇ M is obtained.
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • a phosphate buffer pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid.
  • Solutions a) and b) are emulsified for 10 minutes using a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 270 ml per minute.
  • a gear pump Ismatec® MCP-Z, pump head P1830
  • the primary emulsion is pumped by a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 20 ml per minute
  • a gear pump Ismatec® MCP-Z, pump head P130
  • a pump capacity of 400 ml per minute in a mixing vessel Statischemischer® SMXS DN6.
  • the microparticles are washed by using different cycle of sedimentation/soak-up of supernatant/addition of fresh water (filtration and washing on the filter could be an alternative), the washed microparticles can be freeze dried as a suspension or as powder after filtration. A free-flowing powder consisting of microparticles with an average diameter of 60-70 ⁇ m is obtained.
  • the buffered solution is the solution used for the aqueous solution c) is used without the polyvinylalcohol or any other surface active agents:
  • a phosphate buffer ( ⁇ fraction (1/15) ⁇ M, pH 7.4, 7.24 g KH 2 PO 4 and 30.28 g Na 2 HPO 4 ) is prepared in 4 litres of water at 20° C. The osmolarity of the solution is then adjusted with mannitol to the osmolarity of the protein aqueous solution a) at about 600 mOsm.
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • a phosphate buffer pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid.
  • Solutions a) and b) are emulsified for 10 minutes using a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 270 ml per minute.
  • a gear pump Ismatec® MCP-Z, pump head P1830
  • the primary emulsion is pumped by a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 20 ml per minute
  • a gear pump Ismatec® MCP-Z, pump head P130
  • a pump capacity of 400 ml per minute in a mixing vessel Statischemischer® SMXS DN6.
  • microparticle suspension recovered in a tank is then washed by mean of the cross-flow filtration technology to remove methylenechloride and all the salts and excipients contained in the aqueous outer phase
  • the methylenechloride, salts and excipients are removed through the membrane by mean of the diafiltration mode of the cross-flow filtration.
  • Microparticles are filtered off, dried in a vacuum, and the pre-dried microparticles undergo freeze-drying.
  • the microparticles suspension can as well be concentrated and fill in vial as suspension prior to freeze-drying.
  • a free-flowing powder consisting of microparticles with an average diameter of 60-70 ⁇ m is obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.

Description

  • The invention relates to microparticles comprising at least one biologically degradable polymer, optionally at least one water soluble polymer and at least one pharmacologically active ingredient distributed in the polymer containing a phospholipid or lecithin and a process for their preparation.
  • Microparticles comprising a mixture of a biologically degradable polymer and a water-soluble polymer, into which a pharmaceutical active ingredient, preferably peptides, polypeptides or proteins, are incorporated, are known from U.S. Pat. No. 5,869,103. It is mentioned that an undesired initial high release of active ingredient, especially surface-active proteins, may be suppressed it, during production of the particles, a stabiliser, for example surfactants such as sorbitan monostearate or glyceryl monostearate, is added to the organic phase of an active ingredient emulsion or suspension. When active ingredient is released in contact with a physiological medium, such surfactants are washed out particularly quickly, so that the microparticle composition changes. Therefore, these surface active agents will stay in the polymer matrix for a very short period and will not prevent a possible adsorption of the drug substance to the polymer matrix during the release period. Therefore, a release of active ingredient over a longer period is not achieved.
  • In Pharmaceutical Research, Vol.14, No. 4, pages 420 to 425 (1997), J. L. Cleland describes the encapsulation of a recombinant human growth hormone with a biologically degradable polymer, for example a copolycondensate comprising lactic acid and glycolic acid. In this system, the initial high release of active ingredient can only be reduced, and the possible denaturing of the hormone is avoided by adding trehalose or mannitol.
  • In Biotechnology and Bioengineering, Vol. 65, No. 6, pages 659 to 667 (1999), H. K. Tim et al describe that the encapsulation of the recombinant human growth hormone in a copolycondensate comprising lactic acid and glycolic acid leads to systems which have a high initial release of hormone of up to over 50% and afterwards no longer release any active ingredient. M. Morlock et al. [European Journal of Pharmaceutics and Biopharmaceutics 43 (1997), pages 29-361 and B. Bittner et al. [European Journal of Pharmaceutics and Biopharmaceutics 45 (1998), pages 295-305] describe a similar behaviour when recombinant human erythropoietin is encapsulated in a copolycondensate of lactic acid and glycolic acid.
  • The problem of encapsulating pharmaceutical active ingredients, especially surface-active peptides, polypeptides and proteins in biologically degradable polymers, in order to attain a constant release of active ingredient over a longer period of time without a loss of activity in production and during storage and administration, has not yet been solved in a satisfactory manner.
  • It has now surprisingly been found that, using at least one water insoluble surface active substance from the group of lecithins and phospholipids together with the polymer for the preparation of microparticles, high concentrations of pharmacologically active ingredient in the area of the surface of microparticles may be avoided. The continuous release may last at least over a long period of time without observing a complete breakdown of pharmacologically active ingredient into the surrounding biological medium.
  • In one aspect the invention provides microparticles comprising
      • a) at least one biologically degradable polymer, and
      • b) optionally at least one water soluble polymer, and
      • c) at least one pharmacologically active ingredient distributed in the polymer
      • d) containing a phospholipids or lecithin
  • The microparticles may have an irregular and preferably essentially spherical shape. The particle diameter of the individual microparticles may be 0.1 to 200 μm, preferably 1 to 100 μm, most preferably 1 to 50 μm. Microparticles having an average particle diameter in the range of 5 to 80 μm, preferably 30 to 70 μm, are preferred. The particle size may be controlled, for example, by adjusting the process parameters and by selecting solvents, polymers and the molecular weight of the polymers employed.
  • Depending on the preparation process and the composition, the microparticles may be compact and essentially pore-free particles, or porous particles with a compact or porous surface.
  • As used herein “biologically degradable polymers” means for example those polymers that are decomposed in a physiological medium. Hydrolytically degradable polymers are basically appropriate for this.
  • Biologically degradable polymers are known and are, in part, commercially obtainable. They may be, for example homo- or copolyesters of dicarboxylic acids, alkylene diols, polyalkylene glycols and/or aliphatic hydroxycarboxylic acids; homo- or copolyamides of dicarboxylic acids, alkylene diamines, and/or aliphatic aminocarboxylic acids; corresponding polyester-polyamide copolymers, polyanhydrides, polyorthoesters, polyphosphazenes and polycarbonates. Suitable dicarboxylic acids are, for example, terephthalic acid and especially saturated aliphatic acids of formula HOOC—(CnH2n)—COOH, wherein n is 0 or a number from 1 to 6 (oxalic, malonic, succinic or adipic acid). Alkylene diols may correspond for example to HO—(CxH2x)—OH, wherein x is a number from 1 to 6 (ethane-, propane-, butane-, pentane- or hexanediol). The hydroxycarboxylic acids may correspond to formula HO—(CxH2x)—COOH, wherein x is a number from 1 to 6 (hydroxyacetic acid, hydroxypropionic acid, hydroxybutanoic acid, hydroxypentanoic acid, hydroxyhexanoic acid). The aminocarboxylic acids may correspond to formula H2N—(CxH2x)—COOH, wherein x is a number from 1 to 6 (aminoacetic acid, aminopropionic acid, aminobutanoic acid, aminopentanoic acid, aminohexanoic acid). The polyalkylene glycols in question may be, for example, oligomers of ethylene glycol or propylene glycol with ca. 2 to 100, preferably 2 to 50 monomer units. Polycarbonates may contain recurring structural elements of formula —CO—(CxH2x)—O, wherein x is a number from 1 to 6. The molecular weight of the polymers may be, for example, 500 to 1,000,000, preferably 1000 to 500,000, most preferably 2000 to 100,000 daltons.
  • The biologically degradable polymers may be linear, branched and optionally crosslinked. According to the invention, star polymers may also be used, in which polymer chains are bonded to the functional groups (for example hydroxyl, amino and/or carboxyl groups) of a core monomer, such as saccharides. Such polymers are known and are partly commercial.
  • Preferred biologically degradable polymers are selected from the group of polycarbonates, and in particular the polyesters and polyamides of aliphatic hydroxycarboxylic acids or aminocarboxylic acids. Homo- and copolycondensates of α-hydroxycarboxylic acids are especially preferred, for example glycolic acid and lactic acid. The ratio of monomers in copolycondensates may be, for example, 10:1 to 1:10, preferably 1:4 to 4:1. Especially preferred polycondesates are poly-L- or poly-D,L-lactic acid. Preferred copolycondensates are poly-D,L-lactide/glycolides with a monomer ratio of ca. 1:1 and a molecular weight of 5000 to 100,000 daltons. Mixtures of biologically degradable polymers may also be used. The biologically degradable polymers are essentially insoluble in water.
  • Water-soluble polymers are likewise known and available commercially. They may be, for example, homo- or copolyoxa-alkylene oxides of preferably ethylene and/or propylene glycol, polyacrylamides and hydroxyalkylated polyacrylamides, polymaleic acid and the partial esters or amides thereof, polyacrylic acid and the partial esters or amides thereof, polyvinyl alcohol and the partial esters or ethers thereof, polyvinyl imidazole, polyvinyl pyrrolidone, and natural polymers, for example starch or chitosan. Polyvinyl pyrrolidone is preferred. The water-soluble polymers may have molecular weights of 1000 to 500,000, preferably 1000 to 100,000, most preferably 1000 to 20,000 daltons. Mixtures of water-soluble polymers may also be used. The water-soluble polymers should also be soluble in organic solvents.
  • The amount of biologically degradable polymers may be, for example, 99 to 1% by weight, preferably 90 to 50% by weight, and the amount of water-soluble polymers may be 1 to 99% by weight, preferably 10 to 50% by weight, based on the composition of the polymers.
  • The microparticles contain at least one water-insoluble surfactant from the group of lecithins and phospholipids, the addition of which ensures that the active ingredient is protected against adsorption on the polymer matrix during the whole release period. Due to this effect the invention provides microparticles with extended release of an active ingredient. Lecithins and phospholipids are known and are available commercially. These surfactants may be extracted from natural products such as eggs or soya. The lecithins in question are natural, partly hydrogenated and hydrogenated lecithins or sphingolipids. Natural lecithins are mixtures of different phospholipids. Examples of phospholipids are phosphatidyl choline, phosphatidyl ethanolamine, lysophosphatidyl choline, phosphatidyl glycerine, phosphatidic acid and phosphatidyl serine, as well as the partially or fully hydrogenated derivatives thereof. Examples of phospholipids with defined fatty acids are 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerine, 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-glycerine and 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerine. Lecithin and phosphatidyl choline are preferably used.
  • The amount of lecithins and/or phospholipids may be 0.01 to 90% by weight, preferably 0.1 to 70% by weight, most preferably 0.1 to 20% by weight, based on the total composition of the microparticles. The lecithins and phospholipids are essentially uniformly distributed throughout the volume of the microparticles. Insofar as the lecithins or phospholipids are only partly soluble or insoluble in the solvent of the polymer solution, the formation of a dispersion of these substances in the polymer solution may be sufficient to achieve the effects according to the invention.
  • The pharmacologically active ingredients are in general those that are stable under the preparation conditions. Water-soluble active ingredients are preferred. Peptides, polypeptides and proteins are preferred according to the invention, especially those which adhere to the surface of microparticles because of their surface-active properties and lead to the formation of agglomerates. Further examples are carbohydrates, oligonucleotides, RNA and DNA. A few examples of peptides, polypeptides and proteins are antibodies, growth hormones, insulin, interferons, erythropoietin, calcitonin, heparin, somatostatins, cell-stimulating factors and parathyroid hormones. The aqueous solutions may contain buffers and electrolytes, for example NaCl. Examples of interferons are interferons of the alpha group, preferably interferon alpha 2a or alpha 2b, most preferably interferon alpha 2b.
  • The amount of active ingredient in the microparticles may be 0.1 to 90% by weight, preferably 1 to 70% by weight, most preferably 1 to 20% by weight, based on the weight of the microparticles.
  • Preparation processes for microparticles are known per se and are described in relevant literature. According to the invention, the water-insoluble and surface-active substances are hereby added to the polymer solution, thereby providing optimum protection of the pharmacologically active ingredients during encapsulation and good distribution of the substance in the polymer of the microparticles.
  • The particles may be produced, for example by dispersing solid active ingredients or emulsifying liquid active ingredients or active ingredient solutions in physiologically compatible solvents in a polymer solution containing at least one surface-active substance, and subsequently removing the solvent. Evaporation may be undertaken at high agitation speeds in order to form the particles. It is expedient to carry out spray-drying.
  • Microparticles may also be produced by precipitating the polymer through the addition of a solvent, in which a polymer is insoluble, at high agitation speeds, whereby the pharmacologically active ingredient or the solution of an active ingredient is embedded in the polymer of the formed microparticles.
  • In another aspect the invention provides a method of producing microparticles by forming polymers from polymer precursors (for example monomers and/or prepolymers) in a dispersion or emulsion of an active ingredient or active ingredient solution with the polymer precursors at high agitation speeds. Dispersed or emulsified pharmacologically active ingredient is hereby coated and precipitated by separating the polymer.
  • In a further aspect of the Invention microparticles may be formed by using encapsulation by means of polymer separation in multi-phase systems of aqueous and organic media, which are similarly known. For example, it is possible to emulsify aqueous solutions, dispersions or emulsions of active ingredient in an organic polymer solution, and then to emulsify this emulsion in turn in water, in order to then form the microparticles by removing the solvent. Furthermore, solutions, dispersions or emulsions of active ingredient in an organic solvent can also be emulsified in water, this emulsion is then emulsified in an organic polymer solution, and afterwards the polymer is then precipitated by adding a solvent which is immiscible with the polymer solution.
  • The water-insoluble and surface-active substances are hereby added to the polymer solution, thereby providing optimum protection for the active ingredients during encapsulation, with good distribution of the substance in the polymer of the microparticles.
  • Water-soluble pharmacologically active ingredients and in particular water-soluble, optionally surface-active peptides, polypeptides and proteins are preferably used as the aqueous formulation for encapsulation, whereby it is particularly advantageous to form the microparticles in a three-phase system.
  • A further object of the invention is a process for the preparation of microparticles, comprising the steps
      • a) preparation of an aqueous solution e.g. a phosphate buffer of at least one pharmacologically active ingredient
      • b) preparation of a solution of a biodegradable polymer and optionally a water soluble polymer as well as a surface active substance e.g. a phospholipid or lecithin in an organic solvent which is insoluble in water e.g. methylenechloride.
      • c) mixing a surfactant e.g. polyvinyl alcohol with phosphate buffer to form an aqueous solution
      • d) mixing solution a) and b) using a gear pump to form an emulsion
      • e) pumping emulsion d) and the aqueous solution c) with a gear pump to a static mixer and mixing them in the static mixer to form a water in oil in water emulsion
      • f) removing e.g. evaporating the solvent from emulsion e)
      • g) separating the microparticles by sedimentation (optionally by filtration) and freeze-drying
  • Depending on the solubility of the pharmacologically active ingredient and the desired dosaging thereof, the aqueous solution of process step a) may contain 0.01 to 80%, preferably 0.1 to 60%, most preferably 0.1 to 30% by weight of pharmacologically active ingredient, based on the aqueous solution. The solution may contain stabilising agents and/or water-soluble thickeners. If peptides, polypeptides or proteins are used, it is expedient to add pH buffers, e.g. phosphate buffers. In the case of peptides, polypeptides or proteins, it is also advantageous to add protecting agents, for example glycine or sugar. The components may be mixed and dissolved by stirring, optionally whilst heating. Any insoluble constituents can be filtered off before further use.
  • The polymers and the surface-active substance are conveniently dissolved whilst stirring, optionally with heating. Any insoluble constituents can be filtered off before further use. The amount of biologically degradable polymer in the solution may be, for example, 1 to 60%, preferably 0 to 50% by weight, the amount of water-soluble polymer 0 to 50% by weight, and the amount of surface-active substance 1 to 80%, preferably 2 to 40% by weight, whereby the percentages by weight add up to 100%. Suitable solvents, which are immiscible with water, are for example hydrocarbons, halogenated hydrocarbons and ketones. Preferred solvents are halogenated hydrocarbons, for example chloroform, ethane trichloride or tetrachloride, and in particular methylene dichloride.
  • In order to form an emulsion of the active ingredient solution (a) in the solution of polymers and surface-active substances (b), the solutions are mixed by agitating at high speed. The volume ratio of solution a) to solution b) may be, for example, from 1:1 to 1:50, preferably from 1:2 to 1:10. We have found out that this emulsion forming step may be carried out in a particularly advantageous manner by using a gear pump.
  • Gear pump technology is well known. Rotary gear pump may be based on meshing gears. Gear pumps are positive displacement pumps utilizing a set of gears as the displacement device. The fluid pumps may have e.g. helical gears (angled teeth), spur gears (straight teeth), or herringbone gears.
  • A typical gear pump includes at least two and sometimes at least three gears including a drive gear and a driven gear housed within a pumping chamber. Gear pumps are preferred by the present applicants because of their quiet operation, hydraulic efficiency, conjugate mechanical motion, constant sealing of the surfaces between the mating gear flanks and the minimum entrapment of fluid between the teeth that are in contact. The gear pump may have a high load carrying capacity and run more smoothly.
  • The gear pump may be based on cavity technology. Such gear pumps typically consist of a housing having an inlet, a liquid conduit and an outlet. In the housing is a gear cavity, within which gears meshingly engage and rotate. Liquid enters the gear cavity near the engagement of the gears and on a side wherein the gear teeth are disengaging. As liquid enters the gear cavity it is entrained between the gear teeth and the walls of the gear cavity and moved along the periphery of the gear cavity until it reaches the point at which the gear teeth engage. This action sets up a pressure differential between the liquid inlet and the liquid outlet causing liquid flow.
  • Such gears intermesh with their teeth to produce high local shear forces to form an emulsions. Gear pumps are preferred pumps to create the shear stress in a closed chamber without creation of air/liquid interfaces that are detrimental to the stability of sensitive active ingredient as proteins and peptides.
  • Preferably a pump having a magnetic drive is used for aseptic manufacture of microparticles. The pump head is coupled with the driving pump and can be easily removed for sterilization. A magnetic drive pump may have an outer annular magnet turned or rotated by a motor. An annular inner magnet may be disposed within the outer magnet and may be carried on a pump shaft. The inner magnet may be isolated from the outer magnet by a thin metallic or plastic cup. The inner magnet of such pumps may include a magnet and flux ring assembly which operates in the liquid that is moved through a system by the pump.
  • The gear pump may have suction shoes of the type shown in U.S. Pat. No. 4,127,365 the edge of the shoe fitting within the groove in each gear and bearing against the bottom of the groove. The shoe may form a passageway from the liquid inlet duct in the gear block (which is covered by the shoe) to the mesh point of the gear teeth. The shoe may fit over the mesh point of the gears and at least a span of two teeth to either side thereof, also fitting over the inlet duct and thus isolating this area from the main pump cavity to establish a small pump chamber within the pump cavity. Since there is a pressure differential when the pump is operating which is lower on the underside of the shoe than in the main pump cavity, the shoe is held against the pump block. The shoe separates the inlet duct from the discharge pressure, while accepting fluid flow.
  • The technology of gear pumps using magnetic drives is disclosed e.g. in U.S. Pat. Nos. 4,414,523 and 6,007,312. Gear pumps are disclosed e.g. in U.S. Pat. Nos. 4,846,641, 4,414,523, 5,702,234, 5,908,067, 4,493,625, 6,007,312 and 6,033,193. The contents of these patent specification are hereby incorporated by reference.
  • Such pumps may be the Micropump Ismatex brand obtained e.g. from Ismatec A G, Germany or Allschwil, Basel Switzerland. A typical model is IP65
  • Typical flow rates may be e.g from about 1 ml/min to about 12000 ml/min e.g 300 ml/min Typical drive speeds may be e.g from about 60 rpm to about 6000 rpm e.g 3000 rpm Typical differential pressures may be e.g from about 0.1 to about 5.2 bar (75 psi).
  • The present invention provides the unforeseen use of gear pumps to form emulsions. Using gear pumps emulsions may be formed in an aseptic environment.
  • Emulsion (d) is subsequently mixed with water (c) whilst stirring at high speed to form a water in oil in water emulsion. The water may contain stabilisers, for example polyvinyl alcohol or gelatin and buffers. The amount of stabilisers may be 0.01 to 20%, preferably 0.01 to 10% by weight, based on the aqueous solution of the stabiliser. Advantageously this emulsion step is carried out using a static mixer.
  • Using a static mixer, e.g a static laminar mixing device homogenization may be effected by the flow through the mixer. Generally, these devices have been built up of the so-called static mixer elements. These elememts may be present to upset the flow of the liquids and mix them. Shear forces may be determinated by the number and type of mixing elements and by the flow of liquids through the static mixer.
  • Such laminar mixers may be employed in mixing devices for the mixing of low-viscosity soluble additives to high-viscosity liquids. During mixing, the lower-viscosity (limpid) liquid may be fed to the main flow of the highre-viscosity (viscid) liquid, e.g., via a tube which may be arranged before or directly at the inlet to the mixer.
  • We have found that using a static mixer emulsions and microparticles having a controlled, predictable, and narrow cell size distribution may be obtained.
  • Energy required for liquid flow may be produced by pumps or the like.
  • A typical mixer is Sulzer Mixer SMXS DN6 obtainable from Sulzer A G, Winterthur, Switzerland.
  • Typical flow rates of the first liquid (e.g. the internal phase) containing the organic solvent may be e.g from about 1 ml/min to about 12000 ml/min e.g 20 ml/min.
  • Typical flow rates of the second liquid (e.g. the continuous phase) containing water may be e.g from about 1 m/min to about 12000 ml/min e.g 400 ml/min Typical pressure drops may be e.g from about 0.1 to about 5.2 bar (75 psi)
  • Process steps b) to f) are preferably carried out at room temperature.
  • Removal of the organic solvent is advantageously undertaken with further stirring and by applying a vacuum. Heating can mean a temperature of up to ca. 60° C.
  • The microparticles may optionally be washed to purify them (to remove organic solvent and surfactants such as polyvinyl alcohol or gelatin) and then isolated by sedimentation or optionally by filtration and dried to remove water and any residual solvents. The known freeze-drying process is an especially suitable process for this.
  • Process step f) may be replaced by cross-flow filtration. Cross-flow filtration affords the circulation of the microparticle suspension tangentially to a membrane e.g. a polymer membrane (Polyethersulfone Pall membrane type Omega), e.g. a ceramic membrane, e.g. hollow fibers or e.g. spiral wound systems. The pore size of these membranes may be from 0.1 to 1 micrometer, preferably 0.8 micrometer for microfiltration. For ultrafiltration, membranes with molecular weight cut off ranging from 100 to 1,000,000 daltons are used. The suspension is recirculated untill organic solvents and surfactants as e.g. polyvinyl alcohol or e.g. gelatin are removed. Microparticles may collected by sedimentation or by filtration.
  • We have found that microparticles therefrom having a controlled, predictable, and narrow cell size distribution may be obtained.
  • Typical flow rates tangentially over the membrane are e.g. from about 1 ml/min to about 100,000 ml/min e.g. 15,000 ml/min
  • Typical pressure drops may be e.g. from about 0.01 to about 5 bars.
  • After drying, microparticles are obtained in the form of free-flowing powders, which can be easily handled and further processed. The microparticles are essentially free from agglomerates.
  • Microparticles may be resuspended in an aqueous solution containing a bulking agent (e.g. mannitol or sucrose). This suspension may be freeze-dried to get lyophilized microparticles with advantageous storage properties.
  • The structure of the microparticles depends mainly on the preparation process, the consistency of the active ingredients or their solutions, and the choice of polymers or polymer mixtures.
  • Encapsulation of solid active ingredients and of active ingredients dispersed in polymer solutions leads to essentially compact particles with little to no porosity. Release of the active ingredient in contact with a physiological medium is determined in the case of such particles by the decomposition of the polymer. Release can be accelerated by adding water-soluble polymers, since porous structures can be formed through the dissolving of water-soluble polymers. The surface-active substance then protects the active ingredient, so that a delayed release of active ingredient remains assured.
  • Using the water in oil in water process, an aqueous solution containing the active ingredient is emulsified in the polymer solution. After drying, the water contained in droplets of this primary emulsion are removed and the previous droplets form then cavities in the -dried polymer matrix. The cavities are distributed randomly throughout the volume. The size of the cavities distributed throughout the volume depends on the particle size, the process parameters, the selected polymers, their quantitative composition, and the type and amount of surface-active substance. The diameter of the cavities may be, for example, from 0.01 to 100 μm, depending on the size of the microparticles. The cavities are partially or wholly filled with an aqueous, solution of at least one pharmacologically active ingredient. The microparticles may have pores in the surface area, especially if water-soluble polymers are used concurrently during preparation, or if solutions, emulsions and dispersions of active ingredient are not fully encapsulated in the surface area.
  • The microparticles according to the invention are notable for the delayed release behaviour of the pharmaceutical active ingredient in a physiological medium. An initially excessive release (also called initial burst) and a subsequent complete breakdown of the release of active ingredient is not observed, even if surface-active peptides, polypeptides or proteins are used. The delayed release of active ingredient in, for example, blood plasma, can be maintained until the pharmacologically active ingredient in the particles has been used up, which can last for several days up to 12 months, depending on the amount and especially on the polymer used. In a first and second stage, the release of active ingredient may be essentially constant, whereby in the first stage a higher amount, for example 10 to 70% of the total amount of active ingredient, is delivered in a shorter space of time. With the type of composition and the amount of active ingredient in the particles, an optimum dosage can be set, which will suffice for long-term action with single or multiple administration. Using for example the starpolymer poly-D,L-lactide/glycolide the release of an active ingredient may last from several days up to 8 weeks. Using the starpolymer poly-D,L-lactide/glycolide together with interferon alpha 2b the invention provides a favourable release profile over at least 21 days. 10% to 60% of the active ingredient are released in the 2 to 5 days and the remaining active ingredient over a period of at least 21 days.
  • If the microparticles do not contain lecithin or phospholipid in the biologically degradable polymer, then in contrast to the particles according to the invention, no active ingredient is delivered after the initial burst phase. If a water-soluble polymer is additionally incorporated in the polymer matrix consisting of biologically degradable polymer and lecithin or phospholipid, then the active substance is released faster due to the creation of additionnal pores in the polymer matrix. The release period is then shortened and the release process is then essentially based on diffusion and not on a combination of diffusion and polymer degradation.
  • The microparticles according to the invention are suitable for formulating in solid, pasty and liquid formulations for oral application (tablet, coated tablet, capsule, drinking solution or suspension), for parenteral application (syringes for intravenous or intramuscular administration, infusion with suspensions), suppositories for rectal or vaginal application, aerosols for application by inhalation, powders, creams, gels and transdermal systems for subcutaneous application, and drops for nasal or ophthalmic application.
  • Following is a non-limiting description by way of example.
    • A) PREPARATION EXAMPLES Example A1 Preparation of Microparticles
  • a) Preparation of the active ingredient solution
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • b) Preparation of the polymer solution
  • 2561.5 mg of copolycondensate of D,L-lactic acid and glycolic acid (50:50), 640.4 mg of polyvinyl pyrrolidone (PVP K12) and 865.4 mg of lecithin (Epikuron® 200) are dissolved in 20 ml of methylene chloride.
  • c) Preparation of the aqueous phase
  • 40 g of polyvinyl alcohol (PVA Mowiol® 18-88) in phosphate buffer ({fraction (1/15)} M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) are dissolved in 4 litres of water at 20° C.
  • d) Preparation of the primary emulsion
  • Solutions a) and b) are emulsified for 10 minutes using a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 270 ml per minute.
  • e) Preparation of microparticles
  • The primary emulsion is pumped by a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 20 ml per minute, and the aqueous phase is pumped by a gear pump (Ismatec® MCP-Z, pump head P130) at 575 rpm and at a pump capacity of 400 ml per minute in a mixing vessel (Statischemischer® SMXS DN6)
  • f) Methylene chloride is evaporated whilst stirring.
  • g) The microparticles are filtered off, dried in a vacuum, and the pre-dried microparticles undergo freeze-drying. A free-flowing powder consisting of microparticles with an average diameter of 60-70 μm is obtained.
    • Example A2 Preparation of Microparticles
  • The procedure of example Al is followed using the following solutions:
  • a) Preparation of the active ingredient solution
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 2 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • b) Preparation of the polymer solution
  • 2134.6 mg of copolycondensate of D,L-lactic acid and glycolic acid (50:50), 1067.3 mg of polyvinyl pyrrolidone (PVP K12) and 865.4 mg of lecithin (Epikuron® 200) are dissolved in 20 ml of methylene chloride.
  • c) Preparation of the aqueous phase
  • 40 g of polyvinyl alcohol (PVA Mowiol® 18-88) in phosphate buffer ({fraction (1/15)} M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) are dissolved in 4 litres of water at 20° C.
  • Steps d to g are carried out as described in example A1.
  • A free-flowing powder consisting of microparticles with an average diameter of 60-70 μm is obtained.
    • Example A3 Preparation of Microparticles
  • The procedure of example Al is followed using the following solutions:
  • a) Preparation of the active ingredient solution
  • 50.6 mg of recombinant human interferon alpha-2b and 10.12 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • b) Preparation of the polymer solution
  • 2000 mg of copolycondensate of D,L-lactic acid and glycolic acid (50:50), 2000 mg of polyvinyl pyrrolidone (PVP K12) and 1000 mg of lecithin (Epikuron® 200) are dissolved in 20 ml of methylene chloride.
  • c) Preparation of the aqueous phase
  • 40 g of polyvinyl alcohol (PVA Mowiol® 18-88) in phosphate buffer (1/15 M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) are dissolved in 4 litres of water at 20° C.
  • Steps d to g are carried out as described in example A1.
  • A free-flowing powder consisting of microparticles with an average diameter of 60-70 μM is obtained.
    • Example A4 Preparation of Microparticles: Adjustment of the Osmolarity of the Aqueous Outer Phase
  • a) Preparation of the active ingredient solution
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • b) Preparation of the polymer solution
  • 2561.5 mg of copolycondensate of D,L-lactic acid and glycolic acid (50:50), 640.4 mg of polyvinyl pyrrolidone (PVP K12) and 865.4 mg of lecithin (Epikuron® 200) are dissolved in 20 ml of methylene chloride.
  • c) Preparation of the aqueous phase
  • 40 g of polyvinyl alcohol (PVA Mowiol® 18-88) in phosphate buffer ({fraction (1/15)} M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) are dissolved in 4 litres of water at 20° C. The osmolarity of the solution is then adjusted with mannitol to the osmolarity of the protein aqueous solution a) at about 600 mOsm.
  • d) Preparation of the primary emulsion
  • Solutions a) and b) are emulsified for 10 minutes using a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 270 ml per minute.
  • e) Preparation of microparticles
  • The primary emulsion is pumped by a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 20 ml per minute, and the aqueous phase is pumped by a gear pump (Ismatec® MCP-Z, pump head P130) at 575 rpm and at a pump capacity of 400 ml per minute in a mixing vessel (Statischemischer® SMXS DN6).
  • f) Methylene chloride is evaporated whilst stirring.
  • g) The microparticles are washed by using different cycle of sedimentation/soak-up of supernatant/addition of fresh water (filtration and washing on the filter could be an alternative), the washed microparticles can be freeze dried as a suspension or as powder after filtration. A free-flowing powder consisting of microparticles with an average diameter of 60-70 μm is obtained. For washing and freeze-drying the microparticles are suspended in the buffered solution and filled in vials as suspension prior to lyophilization., The buffered solution is the solution used for the aqueous solution c) is used without the polyvinylalcohol or any other surface active agents:
  • A phosphate buffer ({fraction (1/15)} M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) is prepared in 4 litres of water at 20° C. The osmolarity of the solution is then adjusted with mannitol to the osmolarity of the protein aqueous solution a) at about 600 mOsm.
    • Example A5 Preparation of Microparticles: Use of the Cross-Flow Filtration Technology to Wash the Microparticles Suspension
  • a) Preparation of the active ingredient solution
  • 216.36 mg of recombinant human interferon alpha-2b and 43.27 mg of glycine are dissolved in 3 ml of a phosphate buffer (pH 7.5, 25 mM potassium and sodium hydrogen phosphates, 130 mM NaCl, 0.3 mM ethylenediamine tetraacetic acid).
  • b) Preparation of the polymer solution
  • 2561.5 mg of copolycondensate of D,L-lactic acid and glycolic acid (50:50), 640.4 mg of polyvinyl pyrrolidone (PVP K12) and 865.4 mg of lecithin (Epikuron® 200) are dissolved in 20 ml of methylene chloride.
  • c) Preparation of the aqueous phase
  • 40 g of polyvinyl alcohol (PVA Mowiol® 18-88) in phosphate buffer ({fraction (1/15)} M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) are dissolved in 4 litres of water at 200C.
  • d) Preparation of the primary emulsion
  • Solutions a) and b) are emulsified for 10 minutes using a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 270 ml per minute.
  • e) Preparation of microparticles
  • The primary emulsion is pumped by a gear pump (Ismatec® MCP-Z, pump head P1830) at 200 rpm and at a pump capacity of 20 ml per minute, and the aqueous phase is pumped by a gear pump (Ismatec® MCP-Z, pump head P130) at 575 rpm and at a pump capacity of 400 ml per minute in a mixing vessel (Statischemischer® SMXS DN6).
  • f) The whole microparticle suspension recovered in a tank is then washed by mean of the cross-flow filtration technology to remove methylenechloride and all the salts and excipients contained in the aqueous outer phase c): the microparticle suspension is pumped in a loop and allowed to circulate tangentially to a polymer membrane with a pore size of 0.8 micrometer e.g. polyethersulfone with low binding properties or e.g. ceramic membranes. The methylenechloride, salts and excipients are removed through the membrane by mean of the diafiltration mode of the cross-flow filtration. They are filtered and removed as permeat whereas the microparticles that cannot pass through the membrane stay in suspension and come back in the loop as retentat. The water containing methylenechloride, salts and excipients as PVA that is removed with the permeat is replaced continuously by fresh water in order to keep the volume of the initial microparticles suspension at a constant level.
  • g) Microparticles are filtered off, dried in a vacuum, and the pre-dried microparticles undergo freeze-drying. The microparticles suspension can as well be concentrated and fill in vial as suspension prior to freeze-drying. A free-flowing powder consisting of microparticles with an average diameter of 60-70 μm is obtained.
    • B) APPLICATION EXAMPLES Example B1 In vitro drug release
  • 50 mg of the microparticles according to example A1 are added to a phosphate buffer (pH 7.4, {fraction (1/15)} M, pH 7.4, 7.24 g KH2PO4 and 30.28 g Na2HPO4) and the mixture is maintained at 37° C. Then, at certain intervals, the interferon alpha-2b content in the phosphate buffer is determined. The results are listed in table 1.
    TABLE 1
    content in cumulative content
    time (days) the buffer (mg) in the buffer (mg)
    1 0.75995 0.75995
    2 0.43124 1.19119
    3 0.28770 1.47889
    6 0.34728 1.82617
    8 0.19125 2.01742
    10 0.13053 2.14795
    14 0.11585 2.26380
    17 0.07464 2.33844
    21 0.06015 2.39859
    • Example B2
  • The process is carried out according to example B1 with the microparticles according to example A2. The results are listed in table 2.
    TABLE 2
    content in cumulative content
    time (days) the buffer (mg) in the buffer (mg)
    1 1.03206 1.03206
    2 0.45725 1.48931
    3 0.19730 1.68661
    6 0.17711 1.86372
    8 0.13755 2.00147
    10 0.11351 2.11498
    14 0.15434 2.26932
    17 0.09404 2.36336
    21 0.06710 2.430046

Claims (21)

1-21. (canceled)
22. A process for the preparation of microparticles comprising the steps
a) preparing an aqueous solution of at least one pharmacologically active ingredient;
b) preparing a solution of a biodegradable polymer, a water soluble polymer, and a surface active substance in an organic solvent which is insoluble in water;
c) preparing an aqueous solution of a surfactant;
d) mixing solutions of a) and b) using a gear pump to form an emulsion;
e) pumping emulsion d) and the aqueous solution c) with a gear pump to a static mixer and mixing them in the static mixer to form a water in oil in water emulsion;
f) removing the organic solvent from emulsion e); and
g) separating the microparticles.
23.The process of claim 22, wherein the surface active substance of step b) is a phospholipid or lecithin.
24. The process of claim 22, wherein a phosphate buffer is used for the preparation of the aqueous solutions of step a) and c).
25. The process of claim 22, wherein the organic solvent of step c) is methylene chloride.
26. The process of claim 22, wherein the surfactant of step c) is polyvinyl alcohol.
27. The process of claim 22, wherein the organic solvent in step f) is removed by evaporation.
28. The process of claim 22, wherein the microparticles of step g) are separated by sedimentation or filtration.
29. The process of claim 22, wherein the obtained microparticles are freeze-dried.
30. The process of claim 23, wherein the amount of phospholipid or lecithin is from about 0.01 to about 90% w/w of the final microparticle weight.
31. The process of claim 22, wherein the biodegradable polymer is chosen from at least one of homo- or copolyester of dicarboxylic acid, alkylene diol, polyalkylene glycol and/or aliphatic hydroxycarboxylic acid; homo- or copolyamide of dicarboxylic acids, alkylene diamine and/or aliphatic aminocarboxylic acid; corresponding polyester-polyaminde copolymer; polyanhydride; polyorthoester; polyphosphazene; and
polycarbonates.
32. The process of claim 31, wherein the biodegradable polymer is poly-L- or poly-D,L-lactic acid or poly-D,L-lactide/glycolide with a monomer ratio of ca. 1:1 and a molecular weight of 5000 to 100,000 daltons.
33. The process of claim 22, wherein the water soluble polymer is polyvinyl pyrrolidone.
34. The process of claim 23, wherein the phospholipid is phosphatidyl choline.
35. The process of claim 22, wherein the active ingredient is a peptide, a polypeptide or a protein.
36. The process of claim 35, wherein the active ingredient is selected from at least one of antibodies, growth hormones, insulin, interferons, erythropoietin, calcitonin, heparin, somatostatins, cell-stimulating factors and parathyroid hormones.
37. The process of claim 36, wherein the interferon is interferon alpha 2b.
38. The process of claim 22, wherein the organic solvent is removed from the microparticles using cross-filtration technology by circulating emulsion e) tangentially to a membrane at a constant flow wherein the organic solvent, salts and excipients are removed through the membrane, replacing water removed through the membrane by fresh water.
39. Microparticles comprising
a pharmaceutically active ingredient;
at biodegradable polymer;
a water soluble polymer;
a phospholipid or lecithin;
wherein the microparticles are obtained by the process of claim 22.
40. The microparticles of claim 39 having a diameter of 0.1 to 200 μm.
41. The microparticles of claim 39 comprising 1 to 20% by weight active agent, based on the weight of the microparticles.
US10/506,822 2002-03-13 2003-03-12 Pharmeutical microparticles Abandoned US20050152980A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/218,639 US8110224B2 (en) 2002-03-13 2008-07-17 Pharmaceutical microparticles
US13/348,114 US8460709B2 (en) 2002-03-13 2012-01-11 Pharmaceutical microparticles
US13/871,064 US20130236550A1 (en) 2002-03-13 2013-04-26 Pharmaceutical microparticles

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10211040.9 2002-03-13
DE10211040 2002-03-13
DE10213856.7 2002-03-27
DE10213856 2002-03-27
PCT/EP2003/002565 WO2003075892A1 (en) 2002-03-13 2003-03-12 Pharmaceutical microparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/218,639 Continuation US8110224B2 (en) 2002-03-13 2008-07-17 Pharmaceutical microparticles

Publications (1)

Publication Number Publication Date
US20050152980A1 true US20050152980A1 (en) 2005-07-14

Family

ID=27806083

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/506,822 Abandoned US20050152980A1 (en) 2002-03-13 2003-03-12 Pharmeutical microparticles
US12/218,639 Expired - Fee Related US8110224B2 (en) 2002-03-13 2008-07-17 Pharmaceutical microparticles
US13/348,114 Expired - Fee Related US8460709B2 (en) 2002-03-13 2012-01-11 Pharmaceutical microparticles
US13/871,064 Abandoned US20130236550A1 (en) 2002-03-13 2013-04-26 Pharmaceutical microparticles

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/218,639 Expired - Fee Related US8110224B2 (en) 2002-03-13 2008-07-17 Pharmaceutical microparticles
US13/348,114 Expired - Fee Related US8460709B2 (en) 2002-03-13 2012-01-11 Pharmaceutical microparticles
US13/871,064 Abandoned US20130236550A1 (en) 2002-03-13 2013-04-26 Pharmaceutical microparticles

Country Status (5)

Country Link
US (4) US20050152980A1 (en)
EP (1) EP1485070A1 (en)
JP (3) JP4679822B2 (en)
AU (1) AU2003221497A1 (en)
WO (1) WO2003075892A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116729A1 (en) * 2005-11-18 2007-05-24 Palepu Nageswara R Lyophilization process and products obtained thereby
WO2008007870A1 (en) * 2006-07-14 2008-01-17 International Gfc Apparatus for preparing particulate lecithin wax composition
US20090092665A1 (en) * 2007-10-08 2009-04-09 Lux Biosciences, Inc. OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS
US9017725B2 (en) 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
WO2017077066A1 (en) 2015-11-06 2017-05-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same
US11622991B2 (en) 2017-05-12 2023-04-11 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075892A1 (en) * 2002-03-13 2003-09-18 Novartis Ag Pharmaceutical microparticles
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
EP1848410A4 (en) * 2005-02-17 2011-11-09 Medivas Llc Polymer particle delivery compositions and methods of use
CN100540585C (en) * 2006-08-02 2009-09-16 四川大学 Contain Biodegradable polyester of phosphatidyl choline group and preparation method thereof
US20110223216A1 (en) * 2008-11-17 2011-09-15 Wayne State University Nanoparticles and Porous Particles and Methods of Making the Same
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
DE19177059T1 (en) 2010-10-01 2021-10-07 Modernatx, Inc. RIBONUCLEIC ACID CONTAINING N1-METHYL-PSEUDOURACILE AND USES
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (en) 2011-10-03 2022-02-25 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
PL2791160T3 (en) 2011-12-16 2022-06-20 Modernatx, Inc. Modified mrna compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
RS63237B1 (en) 2012-11-26 2022-06-30 Modernatx Inc Terminally modified rna
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170326073A1 (en) * 2014-11-25 2017-11-16 Cbc Co., Ltd. Janus nanoparticle and method for producing the same
HUE057613T2 (en) 2015-09-17 2022-05-28 Modernatx Inc Compounds and compositions for intracellular delivery of therapeutic agents
EP3964200A1 (en) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions and methods for delivery of therapeutic agents
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
DK3394093T3 (en) 2015-12-23 2022-04-19 Modernatx Inc PROCEDURES FOR USING OX40 LIGAND CODING POLYNUCLEOTIDES
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
KR20210145306A (en) * 2016-05-13 2021-12-01 메르크 파텐트 게엠베하 Particle size and distribution of polymer for melt extrusion application
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
DK3596042T3 (en) 2017-03-15 2022-04-11 Modernatx Inc CRYSTAL FORMS OF AMINOLIPIDS
HRP20230063T1 (en) 2017-03-15 2023-03-17 Modernatx, Inc. Compound and compositions for intracellular delivery of therapeutic agents
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
CA3063723A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
CN115537156A (en) * 2018-04-27 2022-12-30 福莱西因赛特股份有限公司 Compositions and articles comprising complexes of 1-methylcyclopropene with alpha-cyclodextrin
TW202124360A (en) 2019-09-19 2021-07-01 美商現代公司 Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN114340598A (en) * 2019-09-19 2022-04-12 Amw公司 Extruded depot dosage forms for controlled active ingredient release
US11730166B2 (en) 2020-02-03 2023-08-22 Fresh Inset S.A. Stable 1-methylcyclopropene compositions and uses thereof
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US6268053B1 (en) * 1993-03-09 2001-07-31 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6294204B1 (en) * 1995-11-24 2001-09-25 Inhale Therapeutic Systems, Inc. Method of producing morphologically uniform microcapsules and microcapsules produced by this method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432436B2 (en) * 1972-05-13 1979-10-15
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
DE3917617A1 (en) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg MICRONIZED BIODEGRADABLE PARTICLES, PROCESS FOR THEIR PREPARATION AND THEIR USE
FR2651680B1 (en) * 1989-09-14 1991-12-27 Medgenix Group Sa NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES.
DE3934656A1 (en) 1989-10-13 1991-04-18 Schering Ag METHOD FOR PRODUCING AQUEOUS DISPERSIONS
ES2062634T3 (en) * 1990-08-30 1994-12-16 Senju Pharma Co COMPOSITION WITH CONTROLLED RELEASE OF THE PHARMACY.
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
EP0998917A1 (en) * 1993-11-19 2000-05-10 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
JPH10511957A (en) * 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン Surface-modified nanoparticles and methods for their production and use
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
EP0954301A4 (en) * 1996-06-24 2006-03-08 Euro Celtique Sa Methods for providing safe local anesthesia
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
CA2338031C (en) * 1998-07-17 2006-12-05 Sankaram Bhima Mantripragada Biodegradable compositions for the controlled release of encapsulated substances
GB9906695D0 (en) * 1999-03-24 1999-05-19 Secr Defence Vaccine composition
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
ATE462413T1 (en) * 2000-01-14 2010-04-15 Univ Brown Res Found METHOD FOR PRODUCING MICRONIZED FREEZE-DRIED PARTICLES
US20030064105A1 (en) * 2000-08-25 2003-04-03 Myung-Jin Kim Lipophilic-coated microparticle containing a protein drug and formulation comprising same
BR0107942A (en) * 2000-01-28 2004-01-06 Infimed Therapeutics Inc Slow Release Protein Polymers
KR100522277B1 (en) * 2000-04-28 2005-10-18 다나베 세이야꾸 가부시키가이샤 Method for preparing microsphere
WO2003075892A1 (en) * 2002-03-13 2003-09-18 Novartis Ag Pharmaceutical microparticles
AU2003288902A1 (en) * 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US6268053B1 (en) * 1993-03-09 2001-07-31 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6294204B1 (en) * 1995-11-24 2001-09-25 Inhale Therapeutic Systems, Inc. Method of producing morphologically uniform microcapsules and microcapsules produced by this method

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116729A1 (en) * 2005-11-18 2007-05-24 Palepu Nageswara R Lyophilization process and products obtained thereby
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2008007870A1 (en) * 2006-07-14 2008-01-17 International Gfc Apparatus for preparing particulate lecithin wax composition
US20090092665A1 (en) * 2007-10-08 2009-04-09 Lux Biosciences, Inc. OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US8535694B2 (en) 2007-10-08 2013-09-17 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US10265375B2 (en) 2007-10-08 2019-04-23 Aurinia Pharmaceuticals Inc. Ophthalmic compositions
US10973871B2 (en) 2007-10-08 2021-04-13 Aurinia Pharmaceuticals, Inc. Ophthalmic compositions
US9017725B2 (en) 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
WO2017077066A1 (en) 2015-11-06 2017-05-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same
US10953103B2 (en) 2015-11-06 2021-03-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V Composition comprising a biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same
US11622991B2 (en) 2017-05-12 2023-04-11 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Also Published As

Publication number Publication date
US20120107408A1 (en) 2012-05-03
JP2010248271A (en) 2010-11-04
US20130236550A1 (en) 2013-09-12
US20080279955A1 (en) 2008-11-13
WO2003075892A1 (en) 2003-09-18
EP1485070A1 (en) 2004-12-15
JP2014058580A (en) 2014-04-03
US8460709B2 (en) 2013-06-11
US8110224B2 (en) 2012-02-07
AU2003221497A1 (en) 2003-09-22
JP4679822B2 (en) 2011-05-11
JP2005519944A (en) 2005-07-07

Similar Documents

Publication Publication Date Title
US8460709B2 (en) Pharmaceutical microparticles
JP2005519944A5 (en)
EP0752245B1 (en) Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
JP5754319B2 (en) Method for producing liposomes by a two-stage emulsification method using an external aqueous phase containing a specific dispersant, and a method for producing a liposome dispersion or a dry powder thereof using the liposome production method
HU224008B1 (en) Encapsulation method
JP2006508126A (en) Protein-stabilized liposome formulation of pharmaceutical formulation
JP3841309B2 (en) Method for producing microspheres comprising a fluidized bed drying process
JP2007517023A (en) Nanoparticle composition for oral administration containing water-soluble drug and method for producing the same
JP2010511595A (en) Free base gacyclidine nanoparticles
KR20070103468A (en) Pharmaceutical lipid compositions
WO1998014175A1 (en) Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
JP5983608B2 (en) Liposome-containing preparation using dissolution aid and method for producing the same
US10485760B2 (en) Method for producing liposome
US11395999B2 (en) Method for producing liposome and apparatus for producing liposome
PT1317254E (en) Sustained release particle dispersion
US20020086060A1 (en) Process for producing microparticles
EP1296660A1 (en) The controlled release preparation of insulin and its method
EP0551169A1 (en) Liposome composition and production thereof
CN101522177A (en) Microencapsules containing surface-modified microparticles and methods of forming and using the same
CN101618208A (en) Method for preparing sustained-release microspheres containing micronized recombinant human vascular endothelial inhibin
JP2012102043A (en) Method for producing univesicular liposome, univesicular liposome dispersion and dry powder thereof, and method for producing the univesicular liposome dispersion and dry powder thereof
JPH03173813A (en) Production of liposome
Thomas Parenteral Drug Delivery: Injectables
JP2004513706A (en) Method for producing fine particles

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AUSBORN, MICHAEL;LAMBERT, OLIVIER;NAGELE, OSKAR;SIGNING DATES FROM 20040720 TO 20040721;REEL/FRAME:027208/0138